Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Clovis Oncology Inc (CLVS)

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 552,975
  • Shares Outstanding, K 118,410
  • Annual Sales, $ 164,520 K
  • Annual Income, $ -369,210 K
  • 60-Month Beta 1.73
  • Price/Sales 3.32
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CLVS with:

Options Overview Details

View History
  • Implied Volatility 80.50%
  • Historical Volatility 49.56%
  • IV Percentile 26%
  • IV Rank 14.24%
  • IV High 248.67% on 01/08/21
  • IV Low 52.56% on 08/10/21
  • Put/Call Vol Ratio 0.09
  • Today's Volume 7,591
  • Volume Avg (30-Day) 5,880
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 91,784
  • Open Int (30-Day) 77,918

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.49
  • Number of Estimates 5
  • High Estimate -0.45
  • Low Estimate -0.54
  • Prior Year -0.89
  • Growth Rate Est. (year over year) +44.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.23 +10.40%
on 09/14/21
5.00 -6.60%
on 08/30/21
+0.09 (+1.97%)
since 08/24/21
3-Month
4.06 +15.02%
on 08/19/21
6.65 -29.77%
on 06/25/21
-1.62 (-25.76%)
since 06/24/21
52-Week
4.06 +15.02%
on 08/19/21
11.10 -57.93%
on 02/08/21
-1.03 (-18.00%)
since 09/24/20

Most Recent Stories

More News
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026 - Financial News Media

Palm Beach, FL - September 20, 2021 – FinancialNewsMedia.com News Commentary – Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements...

ONCY : 2.15 (-1.38%)
ONC.TO : 2.74 (+0.37%)
CRVS : 6.80 (-3.27%)
IPHA : 6.70 (-4.29%)
SURF : 7.40 (-7.27%)
CLVS : 4.67 (+1.30%)
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026

PALM BEACH,  Fla., /PRNewswire/ -- Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements have helped in the development of more effective,...

ONCY : 2.15 (-1.38%)
ONC.TO : 2.74 (+0.37%)
CRVS : 6.80 (-3.27%)
IPHA : 6.70 (-4.29%)
SURF : 7.40 (-7.27%)
CLVS : 4.67 (+1.30%)
Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program

--Initial data from LuMIERE study of targeted radiotherapy candidate FAP-2286 also expected in 2022

CLVS : 4.67 (+1.30%)
Non-Metastatic Castration Resistant Prostate Cancer Treatment Market- Overview by Manufactures,Business Analysis, Opportunity, Industry Growth, and Forecast to 2029

Research Nester released a report titled ": Global Demand Analysis & Opportunity Outlook 2029"which delivers detailed overview of the global non-metastatic castration resistant prostate cancer treatment...

CLVS : 4.67 (+1.30%)
NOVN : 8.14 (-3.78%)
AZN.LN : 8,845.000 (+2.04%)
Hearing Assistive Technology (HAT) Market: Top Countries Segmented by Applications and Geography Trends, Growth, Revenue, Market Impact and Precise Outlook 2029

Research Nester released a report titled ": Global Demand Analysis & Opportunity Outlook 2029" which delivers detailed overview of the hearing assistive technology (HAT) market in terms of market segmentation...

CLVS : 4.67 (+1.30%)
NOVN : 8.14 (-3.78%)
AZN.LN : 8,845.000 (+2.04%)
Clovis Oncology Announces Availability of and Reimbursement for Rubraca(R) (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca (rucaparib) is now available and reimbursed in Switzerland. The Swiss authority responsible for the authorization and supervision of therapeutic...

CLVS : 4.67 (+1.30%)
Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission ("SEC") to renew its previously established ATM facility under...

JPM : 163.04 (+1.15%)
CLVS : 4.67 (+1.30%)
Clovis (CLVS) Q2 Earnings Miss, PARP Drug Rubraca Sales Down

Clovis (CLVS) reports wider-than-expected loss for second-quarter 2021. Sales of the company's sole marketed drug, Rubraca, decreased year over year due to COVID-19 impacts.

BMY : 60.23 (-0.66%)
VRTX : 183.61 (-0.80%)
RGEN : 323.26 (-0.29%)
CLVS : 4.67 (+1.30%)
Clovis Oncology (CLVS) Reports Q2 Loss, Lags Revenue Estimates

Clovis (CLVS) delivered earnings and revenue surprises of -7.02% and -9.78%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

CLVS : 4.67 (+1.30%)
Clovis: Q2 Earnings Snapshot

BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Wednesday reported a loss of $66.4 million in its second quarter.

CLVS : 4.67 (+1.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations....

See More

Key Turning Points

3rd Resistance Point 4.94
2nd Resistance Point 4.87
1st Resistance Point 4.77
Last Price 4.67
1st Support Level 4.60
2nd Support Level 4.53
3rd Support Level 4.43

See More

52-Week High 11.10
Fibonacci 61.8% 8.41
Fibonacci 50% 7.58
Fibonacci 38.2% 6.75
Last Price 4.67
52-Week Low 4.06

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar